Venture Capital
United Kingdom
01 September 2025
Recognised for its strength in IP litigation, pharma and biotech clients rely on Osborne Clarke LLP for support in high-value UK and UPC litigation, SPCs and data and marketing exclusivity disputes. The practice is also active in ventures – handling spin-outs, technology transfer, commercialisation and investment transactions – and public and private healthcare matters, recently advising on NHS procurement. Practice head Will James is an experienced patent litigator, recently active in biotech disputes before the UPC. The team was further strengthened by the arrival of transactional lawyer Mathilda Davidson from Gowling WLG and competition litigator Aqeel Kadri from Hausfeld & Co LLP in January 2025, as well as IP litigator John Linneker, who joined from Fieldfisher in November 2024. Matthew Edwards is no longer at the firm.
Legal 500 Editorial commentary
Testimonials
Collated independently by Legal 500 research team.
‘The team is highly experienced in privacy issues relating to pharma and medical device companies. They are extremely hands-on and reliable and provide pragmatic advice. I consider them as part of our in-house privacy team.’
‘Marcus Vass, partner, is easily reachable and very helpful when it comes to accommodating our business needs or discussing alternative fee arrangements. Jon Round, senior associate, is very proactive, friendly, and a real expert on data protection, combining legal acumen and business-oriented advice. ’
‘International team, great expertise.’
Key clients
- Amgen
- Santen
- UCL Technology Fund
- BioNTech
- Institute of Cancer Research
- Creo Medical Group
- King's College London
- AviadoBio
- Kaiyan Medical
- SCVC
Practice head
Will James
Other key lawyers
Justin Starling; Marcus Vass; Peter Rudd-Clarke; Mathilda Davidson; Aqeel Kadri; John Linneker